In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NitroMed Inc.

Division of Arbor Pharmaceuticals Inc.
www.nitromed.com

Latest From NitroMed Inc.

STOCKWATCH: Rotten vegetables for biotech's bad actors

The stock market is theater, a company's public show watched daily by churning audiences of thousands, some first-time punters, some gnarly hecklers. For investors, all corporations are merely players, each with their exits and their entrances. And once a quarter, each company takes a curtain call, acknowledging its owner-audience in a ritualized show of humility and subservience.

Metabolic Disorders Infectious Diseases

Deerfield Management Opts For More Private Investment And A New Public Face

Deerfield Management, the $3.5 billion health care hedge fund, is aggressively expanding its investments in private life sciences companies. As many VCs continue to struggle raising new funds Deerfield hopes its shift, combined with a flexible, research-driven approach to investing and a new involvement in the civic and academic activities shaping the sector, will secure its position as a top health care financier.

BioPharmaceutical Business Strategies

Stockwatch: Biotech investing rules, OK?

Life was much simpler for biotech investors in the 1990s. When Human Genome Sciences Inc. (HGSI), completed its IPO in December 1993, the company's price almost doubled after the second day of trading – everyone profited including the bankers, company management and even the company's investors. That pattern mimicked, albeit less spectacularly, the tripling of Genentech's stock price at its IPO back in October 1980, an event which led to the first rule of biotechnology investing: "Buy at IPO".

Gastrointestinal Cardiovascular

Qnexa REMS Should Deter Off-Label Use Of Components, But Not Place Undue Burden

The Endocrinologic and Metabolic Drugs Advisory Committee voted 20-2 in favor of approving the combination of phentermine and topiramate for weight loss during its second review of Vivus’ application.

BioPharmaceutical Advisory Committees
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Arbor Pharmaceuticals Inc.
  • Senior Management
  • Gerald W Bruce, SVP, Commercial Operations
    William BJ Jones, VP, Mktg. & Bus. Dev.
    L. Gordon Letts, PhD, CSO & SVP, R&D
  • Contact Info
  • NitroMed Inc.
    Phone: (781) 266-4000
    45 Hayden Rd.
    Lexington, MA 02421
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register